DOI:
10.1055/s-00000105
Zentralblatt für Gynäkologie
LinksClose Window
References
O'Brien ME, Wigler N, Inbar M. et al.
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
Ann Oncol 2004; 15: 440-449
Search in:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.